23 completed, 7 terminated, 4 unknown, 3 not yet recruiting. 41 Phase 1, 20 Phase 2.
Follow Tretinoin: new trials by email Literature Review of Tretinoin trials Research Report on Tretinoin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance All-trans retinoic acid, Tislelizumab - EGFR-TKI-resistant Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 24 | 2026-10-01 | 2026-09-25 |
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| ATRA and Carfilzomib in Plasma Cell Myeloma Patients All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose -1, All-Trans Retinoic Acid (ATRA) Dose 1 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 42 | 2024-07-29 | 2026-04-03 |
| Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer all-trans retinoic acid, Stereotactic Body Radiation Therapy - Oligometastatic Disease, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 58 | 2024-07-11 | 2025-12-01 |
| A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS Roxadustat in combination with retinoic acid - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Withdrawn | Peking Union Medical College Hospital | 2023-08-01 | 2026-07-07 | |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Tretinoin - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | Dwight Owen | 18 | 2021-10-18 | 2026-07-20 |
| Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) Pembrolizumab, Vibostolimab, Gebasaxturev - Melanoma | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 146 | 2020-06-26 | 2026-08-27 |
| Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) Pembrolizumab, Quavonlimab, Vibostolimab - Melanoma | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 100 | 2020-06-26 | 2026-09-01 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| A Study of TAS1440 With ATRA in Subjects With r/r AML TAS1440, TAS1440 + ATRA - Acute Myeloid Leukemia | Phase 1 | Terminated | Taiho Oncology, Inc. | 52 | 2020-03-15 | 2024-12-09 |
| MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 S6G5T-3, Retin-A® 0.1% Cream - Acne Vulgaris | Phase 1 | Completed | Sol-Gel Technologies, Ltd. | 62 | 2019-06-27 | 2020-03-18 |
| Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid All-trans retinoic acid, Arsenic Trioxide, Realgar-Indigo naturalis formula - Acute Myeloid Leukemia | Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 30 | 2019-02-03 | 2022-03-28 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Nivolumab With Chemotherapy in Refractory MDS Nivolumab, Azacitidine, Fludarabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | St. Petersburg State Pavlov Medical University | 2 | 2017-05-25 | 2019-04-05 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia Cytarabine, all-trans retinoic acid, Arsenic Trioxide - AML | Phase 1 / Phase 2 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2017-02-08 | 2025-05-30 |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) bomedemstat, tretinoin - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 45 | 2016-10-06 | 2023-07-11 |
| Daratumumab in Combination With ATRA all-trans retinoic acid (ATRA) - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Amsterdam UMC, location VUmc | 60 | 2016-07-06 | 2023-04-28 |
Showing 20 of 41. Sign in to see all of them.
Leukemia, Myeloid, Acute (14) · Myelodysplastic Syndromes (11) · Multiple Myeloma (7) · Leukemia (3) · Melanoma (3) · Neoplasm Metastasis (3) · Acne Vulgaris (2) · Anemia, Refractory, with Excess of Blasts (2) · Blast Crisis (2) · Congenital Abnormalities (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Non-Hodgkin (2)
Coria Laboratories, Ltd. (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · University of Bergen (2) · Washington University School of Medicine (2) · Amsterdam UMC, location VUmc (1) · Barts & The London NHS Trust (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Oncology Group (1) · Daniel Breadner (1) · Dwight Owen (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (1)
United States (24) · Australia (4) · China (3) · France (3) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Norway (2) · Switzerland (2) · Belgium (1) · Canada (1) · Mexico (1) · Russia (1) · South Africa (1)
Oystein Bruserud, MD (2) · Adam J Esbenshade (1) · Camille Abboud, M.D. (1) · Carsten Mueller-Tidow, Prof. (1) · Daniel Breadner (1) · Dwight H Owen, MD, MS, FACP (1) · Fred Zheng, MD (1) · Guido Tricot, MD, PhD (1) · Hemant Kocher, Professor (1) · Huaiyu Wang, Dr. (1) · James L Boyer, MD (1) · Jatin J. Shah, MD (1) · Jianxiang Wang (1)
PMID 28877686, PMID 33917201, PMID 18922099, PMID 19007987, PMID 22829110, PMID 24488798, PMID 25975191, PMID 26308596, PMID 26864107, PMID 31242873, PMID 32211336, PMID 32973176, PMID 33495312, PMID 34625791, PMID 39775043, PMID 39863139
2015 (2), 2019 (2), 2023 (2), 2017 (1), P30CA006973 (1), R01CA067803 (1), U10CA180886 (1)